Report
Optimizing the speed & accuracy of clinical trial label translations
How a clinical labeling solution can help you navigate country-specific requirements in the agile era
The management of labeling for clinical trials has always been a complex subject, especially when considering the global nature of most research. Effective clinical trial supply chain management has relied on successfully navigating a complex and ever-evolving web of regulations and process requirements that can radically differ from country to country.
These longstanding challenges have been compounded by the growing demand for agile clinical trial models which were used to great effect in the development of vaccines during the pandemic. Accelerated decision making was made possible by the parallelization of processes, with changes being made to trial protocols at an unprecedented frequency.
Label and booklet production has the potential to create a bottleneck in the clinical trial supply chain if these functions are not managed efficiently. The requirement for localized labels with translated content further complicates the existing challenge. Translations are often the lengthiest part of the entire process when accounting for the use of translation houses alongside internal reviews to ensure regulatory compliance for each country label.
This report looks at how the industry has shifted its approach to optimizing the speed and accuracy of clinical trial label translations, as well as how a clinical labeling solution can help you navigate country-specific requirements in the agile era.
- Regulatory
- GHS
- FDA
- Supply Chain
- Clinical Trials
- Track and Trace
Share